Salient Capital Advisors’s Novo Nordisk NVO Stock Holding History

Salient Capital Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-8,850	Closed	-$238K	–	251
2016 Q2	$238K	Sell	8,850 -78	-0.9%	-$2.14K	0.01%	224
2016 Q1	$242K	Sell	8,928 -50	-0.6%	-$1.34K	0.01%	222
2015 Q4	$261K	Buy	8,978 +128	+1%	+$3.54K	0.01%	220
2015 Q3	$240K	Hold	8,850	–	–	0.01%	217
2015 Q2	$242K	Sell	8,850 -300	-3%	-$8.43K	﹤0.01%	239
2015 Q1	$244K	Buy	+9,150	New	+$211K	﹤0.01%	220
2014 Q4	–	Sell	-9,150	Closed	-$218K	–	248
2014 Q3	$218K	Hold	9,150	–	–	﹤0.01%	214
2014 Q2	$211K	Hold	9,150	–	–	﹤0.01%	220
2014 Q1	$209K	Buy	+9,150	New	+$195K	0.01%	209

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Salient Capital Advisors's NVO Position: Q3 2016 in Review

Salient Capital Advisors sold out of Novo Nordisk (NVO) in Q3 2016, closing a stake of 8,850 shares — an estimated $238K sold.

Salient Capital Advisors first reported a position in NVO in Q1 2014 and held it in 9 quarters. The position peaked at $261K in Q4 2015. 513 funds tracked by Wall St. Rank hold NVO as of Q3 2016.

Salient Capital Advisors reported no remaining Novo Nordisk position as of Q3 2016 after selling out during the quarter.
Salient Capital Advisors sold 8,850 Novo Nordisk shares in Q3 2016, an estimated $238K.
Salient Capital Advisors first reported a position in Novo Nordisk in Q1 2014 and held it in 9 quarters.
Salient Capital Advisors's Novo Nordisk position peaked at $261K in Q4 2015.
513 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2016.

Based on Salient Capital Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.